English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Minnesota's 3rd Congressional District
+
Regulatory
Patient Daily
| May 18, 2026
Former Rep. Paulsen on 340B: The 'program has created a healthcare system where costs are increasing for everyone'
Trending
+
Pharmaceuticals
Patient Daily
| Aug 4, 2026
Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+
Pharmaceuticals
Patient Daily
| Aug 6, 2026
FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+
Regulatory
M. Y. Bailey
| Aug 7, 2026
PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
+
Regulatory
M. R. Armstrong
| Aug 4, 2026
Public Policy Solutions on 340B: 'The program has enriched big hospital execs'